<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="142740">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01662284</url>
  </required_header>
  <id_info>
    <org_study_id>CO12901</org_study_id>
    <nct_id>NCT01662284</nct_id>
  </id_info>
  <brief_title>Study of 124I-NM404 in Advanced Solid Malignancies</brief_title>
  <official_title>A Phase 1/2 Study of 124I-NM404 in Subjects With Advanced Solid Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Wisconsin, Madison</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cellectar Biosciences, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Wisconsin, Madison</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <authority>United States: University of Wisconsin Carbone Cancer Center Data Safety and Monitoring Committee</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      124I-NM404 is a new investigational agent being developed to better identify local tumors
      and cancerous tumors using imaging technologies such as positron emission tomography (PET)
      scans. An investigational drug is a drug that has not been approved by the Food and Drug
      Administration (FDA) and is available for research use only. 124I-NM404 is only taken up by
      the cancer cells, not the normal cells. Compared to traditional methods such as CT (computed
      tomography) or MRI (Magnetic resonance imaging), 124I-NM404 may help physicians more
      accurately see and evaluate cancerous tumors. This agent has been safely studied in animals
      and a limited number of human patients with lung cancer. This study is being done to
      determine the best dose to use and to fully evaluate the images that result from using this
      new agent.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2012</start_date>
  <completion_date type="Anticipated">July 2014</completion_date>
  <primary_completion_date type="Anticipated">July 2014</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic</study_design>
  <primary_outcome>
    <measure>Optimal Imaging Parameters</measure>
    <time_frame>2 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>To determine the optimal imaging parameters (dose, acquisition time, imaging time post injection, normal organ and tumor dosimetry) of 124I-NM404 in subjects with advanced solid malignancies with one of the following tumor types: triple negative breast, prostate, colorectal, gastric, ovarian, pancreatic, esophageal, soft tissue sarcoma, and head &amp; neck cancer</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>2 years</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Number and grade of adverse events attributable to 124I-NM-404</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PET comparison</measure>
    <time_frame>2 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>compare 18F-FDG PET to 124I-NM404 PET</description>
  </secondary_outcome>
  <number_of_arms>9</number_of_arms>
  <enrollment type="Anticipated">81</enrollment>
  <condition>Triple Negative Breast, Prostate, Colorectal, Gastric, Ovarian, Pancreatic, Esophageal, Soft Tissue Sarcoma, and Head &amp; Neck Cancer</condition>
  <arm_group>
    <arm_group_label>Triple Negative Breast</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>124I-NM404 in triple negative breast cancer</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Prostate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>124I-NM404 in prostate cancer</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Colorectal</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>124I-NM404 in colorectal cancer</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Gastric</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>124I-NM404 in gastric cancer</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ovarian</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>124I-NM404 in ovarian cancer</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pancreatic</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>124I-NM404 in pancreatic cancer</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Esophageal</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>124I-NM404 in esophageal cancer</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sarcoma</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>124I-NM404 in soft tissue sarcoma</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Head &amp; Neck</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>124I-NM404 in head and neck cancer</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>124I-NM404</intervention_name>
    <description>124I-NM404 administered at either 5mCi or 3mCi on day 1.</description>
    <arm_group_label>Triple Negative Breast</arm_group_label>
    <arm_group_label>Prostate</arm_group_label>
    <arm_group_label>Colorectal</arm_group_label>
    <arm_group_label>Gastric</arm_group_label>
    <arm_group_label>Ovarian</arm_group_label>
    <arm_group_label>Pancreatic</arm_group_label>
    <arm_group_label>Esophageal</arm_group_label>
    <arm_group_label>Sarcoma</arm_group_label>
    <arm_group_label>Head &amp; Neck</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of advanced solid malignancy.

          -  Allowed tumor types: triple negative breast, prostate, colorectal, gastric, ovarian,
             pancreatic, esophageal, soft tissue sarcoma, and head &amp; neck cancer

          -  Disease must be at least 1cm in diameter

          -  Brain metastasis must be stable for at least one month.

          -  ECOG performance status 0-2

        Exclusion Criteria:

          -  Skin lesions only

          -  Chemotherapy or radiotherapy within 1 week

          -  Residual toxicities of grade 2 or greater from prior therapy

          -  Adequate organ function as per specified laboratory parameter

          -  Platelet count &gt; or = to 160,000/uL
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Glenn Liu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Wisconsin, Madison</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Cancer Connect</last_name>
    <phone>1-800-622-8922</phone>
    <email>cancerconnect@uwcarbone.wisc.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Wisconsin Carbone Cancer Center</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Glenn Liu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2012</verification_date>
  <lastchanged_date>August 7, 2012</lastchanged_date>
  <firstreceived_date>August 3, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Head and Neck Neoplasms</mesh_term>
    <mesh_term>Sarcoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
